Algicler

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Algicler

Property Description
Active ingredient Diclofenac (as sodium salt or acid)
Forms Oral tablets, topical gels, suppositories, injectable preparations
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common purpose Symptomatic relief of pain, inflammation, and fever
Origin Synthetic (Phenylacetic Acid Derivative)

Algicler: What Type of Medicine is Diclofenac?

Algicler is a pharmaceutical preparation whose active component is Diclofenac, which is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification is clinically recognized worldwide for the management of various discomforts linked to inflammation. Diclofenac is a synthetic compound derived from phenylacetic acid, an identity that places it within a specialized group of non-narcotic analgesics. Regulatory entities commonly classify this potent compound as either prescription-only or requiring pharmacist consultation, depending on its specific dosage form and concentration. This establishes its core utility as an anti-inflammatory and analgesic agent, helping to reduce swelling and ease general discomfort.

Composition and Available Preparations of Algicler

The fundamental composition of Algicler centers on Diclofenac as the sole active agent, establishing it as a single-ingredient product (monotherapy). The formulation typically utilizes Diclofenac in salt form, combined with pharmaceutical excipients that determine the final delivery system. The medicine is manufactured in multiple dosage form(s) to suit different therapeutic needs, a differentiating factor that allows for flexibility in application, including forms for oral administration (such as specialized delayed-release or enteric-coated tablets), preparations for topical administration (like gels), and forms for rectal or parenteral routes. This variety ensures the medicine can be targeted either systemically or locally.

General Purpose: How Algicler Provides Symptomatic Relief

The general therapeutic purpose of Algicler is to offer relief by mediating the body's response to irritation and injury, targeting three primary symptomatic issues: pain, inflammation, and elevated body temperature (fever). This therapeutic effect is pharmacologically supported by its fundamental mechanism as an inhibitor of the cyclooxygenase pathway. For example, it provides relief in a typical use scenario such as reducing the swelling associated with a minor musculoskeletal strain. Diclofenac is authorized for its established symptomatic properties against pain and inflammation. Essentially, the medicine helps control the body's overreaction to injury, providing broad symptomatic relief by addressing the underlying chemical cause of discomfort.

What side effects are possible with Algicler ?

Possible Side Effects and Safety Information

The safety profile of Algicler, an NSAID containing Diclofenac, is formally defined by government regulatory authorities (such as the FDA and EMA) through standardized classification of adverse reactions, ensuring a medically grounded communication of potential risks.

Official Adverse Reaction Classification

Adverse reactions are classified into frequency categories—such as Common, Uncommon, and Rare—based on their incidence in clinical data. Many common effects involve the Gastrointestinal Disorders (e.g., headache, dizziness, nausea, diarrhea) and Nervous System Disorders (e.g., headache, dizziness). Other affected systems documented in official labels include Hepato-biliary Disorders, Renal and Urinary Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions and Safety Patterns

The regulatory label emphasizes the potential for Serious Adverse Reactions (SARs), which are rare but clinically significant. These include potentially fatal Cardiovascular Thrombotic Events (such as myocardial infarction or stroke) and Gastrointestinal Adverse Events (bleeding, ulceration, and perforation). The risk of these serious events may increase with the duration of use and can occur without warning symptoms.

Specific regulatory safety constraints prohibit the use of this medicine in the setting of Coronary Artery Bypass Graft (CABG) surgery and during the late stages of pregnancy (from 30 weeks gestation). Additionally, official documents caution that Older Adults are at greater risk for certain serious adverse events, particularly those involving the gastrointestinal tract and kidneys.

Overdose and Emergency Response

Algicler Overdose and when to seek help

Domain Official Regulatory Statements
Documented Manifestations Symptoms following an acute overdose can include nausea, vomiting, epigastric pain, diarrhea, dizziness, drowsiness, and headache. Severe ingestions may result in complications such as confusion, seizures, coma, or delirium.
Severe Outcomes Overdose carries the risk of serious, potentially life-threatening systemic events, including gastrointestinal bleeding, ulceration, or perforation. Acute organ damage may also occur, notably severe hepatic impairment and acute renal failure. Increased risk of myocardial infarction or stroke is a critical regulatory concern.
Emergency Actions Seek medical help right away by contacting emergency services or a poison control center for any suspected overdose. Immediate medical attention is required for signs of a serious cardiovascular event, such as chest pain, shortness of breath, or slurred speech. Management is symptomatic and supportive, as no specific antidote is known for Diclofenac overdose.
Population Considerations Elderly patients are documented as being at a higher risk for serious gastrointestinal events. Patients with underlying cardiac or renal impairment are also at greater risk for worsening organ function and complications.

Connection to the Overall Overdose Profile

The official regulatory profile emphasizes that while initial symptoms may be limited to gastrointestinal or CNS effects, the core danger lies in the potential for severe systemic and organ-specific damage. This structure mandates specific immediate actions, such as seeking urgent medical help for these critical signs, and emphasizes that procedural management is limited to supportive care due to the lack of a specific neutralizing agent. Monitoring of vital signs and renal function is typically required during observation.

Therapeutic Uses of Algicler

What Algicler Treats: Main Uses and Benefits

Algicler is commonly used across domains where additional symptomatic support is needed, helping to address symptoms related to physical discomfort and symptoms that create noticeable physiological strain caused by heightened symptoms. Applied in clinical settings that involve acute or unstable symptom patterns, it is relevant when supportive symptom management is appropriate to help improve comfort and functional stability.

Primary Uses and Symptom Domains: The medication is relevant for managing groups of symptoms associated with acute or episodic changes, including joint-related discomfort found in conditions like osteoarthritis and rheumatoid arthritis, as well as general pain and inflammation from minor sprains and strains, postoperative distress, and episodic pain such as menstrual cramps or fever.

“Algicler is commonly used to help with symptom clusters that interfere with daily functioning, providing supportive relief that may assist with maintaining functional stability.”

Key Therapeutic Benefits

Algicler is relevant for easing discomfort and symptoms related to inflammatory or irritative states in the affected areas. It supports patients during episodes of heightened discomfort, which is key for those dealing with chronic conditions and those in short-term recovery.

Quick Fact: Relief for Inflammation and Pain Algicler is commonly used to help with symptoms related to inflammatory or irritative states and symptoms related to physical discomfort across various clinical contexts.

Regulatory References

  1. NIH StatPearls overview of Diclofenac

Eligibility and Restrictions for Use

Who can and cannot use Algicler?

Eligibility for Algicler (Diclofenac) is determined by strict rules in official regulatory labeling, primarily concerning cardiovascular health, gastrointestinal integrity, and age.

Contraindicated Populations (Must NOT Use) Conditional Use (Caution Advised)
Patients with known hypersensitivity to Diclofenac, aspirin, or any NSAID. Elderly patients (ge 65 years) due to increased susceptibility to adverse reactions.
Individuals with active GI ulceration, bleeding, or perforation. Patients with a history of GI disorders or prior ulceration.
Patients in the setting of Coronary Artery Bypass Graft (CABG) surgery. Mild to moderate hepatic or renal impairment (monitoring is advised).
Patients with established congestive heart failure (NYHA Class II–IV), ischemic heart disease, or other established vascular disease. Patients with significant cardiovascular risk factors (e.g., uncontrolled hypertension).
Pregnant women starting at 30 weeks of gestation (Third Trimester). Females of reproductive potential due to potential for reversible infertility.

Age-Related Eligibility: For many systemic oral forms, safety and effectiveness are not established in children younger than 12 years of age. For pregnancy, use is avoided from about 20 weeks onward and contraindicated in the third trimester. Use is generally not recommended in patients with established cardiovascular disease.

What should I know about interactions with other medicines?

Algicler's interaction profile, as defined in official regulatory documents, is structured around its potential for pharmacokinetic and pharmacodynamic interactions with co-administered substances. This information strictly details the documented interaction patterns and resulting limitations.

Documented Interaction Classifications

Interaction Type Interacting Substances / Classes Official Regulatory Outcome
Pharmacodynamic Risk Anticoagulants (e.g., Warfarin), Antiplatelet Agents (including Aspirin), and SSRIs/SNRIs Co-administration results in an officially increased risk of serious gastrointestinal bleeding.
Renal Interference ACE Inhibitors, ARBs, Diuretics (e.g., Furosemide), and Lithium May diminish the blood pressure effects of these drugs. Increases the documented risk of reduced renal function, which can lead to elevated plasma levels of Lithium.
Metabolic Clearance Voriconazole (a strong CYP enzyme inhibitor) Co-administration leads to a documented increase in Diclofenac systemic exposure, with a rise in peak plasma concentration (C max) and total exposure (AUC).

Administration and Contextual Constraints

The regulatory profile prohibits use in the perioperative setting of Coronary Artery Bypass Graft (CABG) surgery and generally advises against co-administration with other NSAIDs due to additive adverse effects. Specific oral formulations must be taken on an empty stomach because taking them with food is documented to reduce their overall effectiveness. The risk of renal function deterioration is explicitly noted to be greater for elderly, volume-depleted, or renal-impaired patients when combined with ACE Inhibitors or ARBs.

Mechanism of Action

The mechanism of action for Algicler (Diclofenac) is defined by a multi-layered strategy focused on modulating specific chemical and neural signaling pathways that influence the synthesis and transmission of physiological mediators.

Molecular Inhibition of Prostaglandin Synthesis

The core mechanism involves the non-selective inhibition of cyclooxygenase enzymes (COX-1 and COX-2), which are essential for converting arachidonic acid into prostanoid mediators. This action primarily suppresses the synthesis of Prostaglandin E2 (PGE2), a key messenger that sensitizes nerve endings and controls the body's thermoregulatory set point. This initial molecular suppression modifies the early stages of the signaling cascade, reducing the rate of synthesis of these systemic messengers.

Direct Modulation of Nociceptive Signaling Pathways

Beyond chemical suppression, Algicler engages in a secondary mechanism that directly influences nociceptive signaling. It achieves this by acting on targets independent of COX, such as the modulation of specific receptors (e.g., PPARgamma) in the spinal cord and the blockade of peripheral ion channels on sensory neurons. This dual approach alters the signaling dynamics within central and peripheral pathways.

Sustained Localized Mechanistic Activity

Algicler possesses a unique pharmacodynamic property that allows the active molecule to accumulate and persist within targeted tissues, such as joint fluid, even as its concentration in the bloodstream declines. This sustained presence ensures continuous enzyme inhibition directly at the site where inflammatory mediators are being overproduced, maintaining local enzyme inhibition.

Dosage and Administration Information

How to use Algicler

Algicler (Diclofenac) usage is governed by the principle of utilizing the lowest effective dose for the shortest duration necessary to achieve symptomatic relief. The medicine is approved for administration via several routes, including oral (tablets, capsules, powders), topical (gels, solutions), and parenteral (IV/IM), allowing for systemic or localized application based on the prescribed need.

Standard adult dosing schedules and maximum daily doses are defined by the specific condition being addressed. For chronic use, such as in the maintenance phase for osteoarthritis, the typical daily oral range is 100 mg to 150 mg administered in divided doses, or 100 mg once daily for extended-release preparations. These daily limits must not be exceeded.

Administration conditions vary by form. Certain oral preparations, including the powder for solution, must be taken on an empty stomach to optimize absorption. Conversely, all delayed-release and extended-release tablets must be swallowed whole and must not be crushed or chewed to preserve the intended release profile. For older adults, guidance emphasizes using the lowest effective dose, while topical forms require application only to clean, intact skin.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Algicler (Diclofenac)


Evidence for Symptomatic Relief in Osteoarthritis

Algicler, which contains diclofenac, was studied in research exploring symptomatic patterns associated with chronic conditions like osteoarthritis (OA). The research exploring how symptoms change over time mainly relies on short-term Randomized Controlled Trials (RCTs), typically lasting 4 to 12 weeks. These studies often included adults with OA, and studies monitored outcomes related to physical discomfort and objective measured changes in walking ability or how patients reported their overall condition. Follow-up durations were limited in most of the core efficacy RCTs. Therefore, there is limited information for long-term outcomes regarding the sustained maintenance of physical function beyond these initial trial periods.


Research Base for Rheumatoid Arthritis and Related Inflammatory Conditions

The active ingredient in Algicler was evaluated in the context of chronic inflammatory diseases, including rheumatoid arthritis (RA). The evidence here is supported by systematic reviews, pooled analyses from large trials, and cohort studies. Research has explored how the active ingredient was observed in patients with conditions characterized by fluctuating manifestations and outcomes linked to inflammatory or irritative states.

Studies focusing on these conditions involving periods of heightened symptoms did include quality of life measures, and research examined changes in joint pain and swelling. Evidence quality varies across studies when interpreting the specific impact on certain long-term disease measures, as many older studies were not designed to meet all current methodological standards.


Studies on Acute Pain and Short-Term Inflammation

The active ingredient in Algicler was studied for research exploring short-term symptom changes in acute pain, such as discomfort following minor surgery or episodic pain like menstrual cramps. The research relies on very short-term, single-dose RCTs. These trials were applied in research contexts involving fluctuating or unstable symptoms, with the main goals being to measure the time until a specific reduction in pain was first reported and the overall change in pain intensity over a window of a few hours. Systematic Reviews reported patterns consistent with data showing a change in the need for additional pain medication (rescue medication).


Research Gaps and What Remains Uncertain

This final section synthesizes the areas where data are limited, including a discussion of the major evidence gaps, inconsistencies, and what regulators or peer-reviewed literature indicate remains unknown about Algicler's research profile.

Key Studies & References

  1. Diclofenac Sodium Delayed-Release Tablets FDA Label (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Algicler (FAQ)

Q: Is Algicler an anti-inflammatory drug or a pain reliever?

Official descriptions classify this medicine as a non-steroidal anti-inflammatory drug (NSAID). The medicine is described as having dual properties, providing both anti-inflammatory effects and pain relief (analgesia).

Q: How is Algicler different from other medicines in the same treatment class?

Official descriptions indicate that Algicler’s mechanism of action includes processes beyond the inhibition of COX enzymes, which is common in its class. Regulatory texts describe secondary actions, such as modulating specific signaling pathways in the nervous system, which are understood to contribute to the medicine’s overall profile.

Q: Is Algicler safe for long-term use?

Regulatory documents address the risks associated with the duration of use. Official product information states that the potential for serious side effects, including cardiovascular events and gastrointestinal complications, may increase over time. Official guidance emphasizes the use of the lowest effective dose for the shortest period necessary to achieve relief.

Q: How long after starting Algicler should I expect to see any difference?

Studies indicate that for certain immediate-release oral forms of Algicler taken on an empty stomach, the active substance typically reaches its peak concentration in the bloodstream within 1.5 to 3 hours. This measurement, known as peak plasma concentration, describes the time required for full absorption into the system.

Q: Can people with pre-existing kidney or liver issues safely use Algicler?

Official safety information notes that this medicine class carries a potential for adverse effects on the kidney and liver systems. For individuals with existing conditions involving these organs, regulatory documents state there is a documented greater risk for adverse events when using medicines in this class.

Q: Is Algicler recommended for pregnant or breastfeeding women, according to official sources?

The official safety constraints prohibit the use of Algicler during the last trimester of pregnancy (from 30 weeks gestation) due to risk to the fetus. Use is generally not recommended after 20 weeks. For breastfeeding, official information states that the substance passes into breast milk in small amounts; some experts describe this as acceptable, but other medicinal options may be preferred.

Q: How long does Algicler stay in the system after the last dose is taken?

Studies show that the active substance has a relatively short half-life of approximately 1.5 to 2 hours in the bloodstream. Official pharmacokinetic research also indicates that the active molecule persists for longer periods in targeted tissues, such as joint fluid. This sustained presence at the site of action is understood to contribute to its effects.

Q: Are there any specific food or diet restrictions while using Algicler?

Official administration instructions note that certain oral forms, such as the powder for solution, are to be taken on an empty stomach to optimize absorption. This condition is necessary to optimize the way the medicine is absorbed into the body. Taking other oral forms with food may potentially delay the onset of absorption.

Q: What percentage of clinical trial participants experienced the most common side effect of Algicler?

Official labels classify adverse reactions into categories like Common, Uncommon, and Rare, based on their incidence in clinical data. The most common side effects, such as nausea and headache, are typically reported to occur in more than 5% of participants. Specific percentages are also provided by regulatory authorities for rare but clinically serious events.

Q: Is Algicler safe for people with pre-existing heart conditions?

Regulatory documents contain warnings regarding the potential for serious cardiovascular thrombotic events, which include heart attack and stroke. The risk for such events may be greater in individuals who have known cardiovascular disease or existing risk factors. The medicine is contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Q: Is it safe to take Algicler with pain relievers other than NSAIDs?

Official patient counseling information emphasizes the importance of informing a healthcare professional about all co-administered prescription and over-the-counter medicines. This includes vitamins, supplements, and any other pain relievers being taken. Disclosing this information helps address potential interactions.

Q: What are the most common reasons doctors prescribe Algicler?

Official documents list the specific conditions for which Algicler is approved for symptomatic relief. These include chronic conditions such as osteoarthritis and rheumatoid arthritis, as well as certain forms of short-term pain, such as menstrual cramps.

Q: Can Algicler affect my ability to sleep?

According to the official list of adverse reactions, effects on the nervous system are sometimes reported. These reported effects include symptoms such as insomnia (difficulty sleeping).

Q: Is Algicler known to cause weight gain or weight loss?

Official reports listing adverse reactions occasionally include metabolic and nutritional effects. These reported effects are generally described by regulatory bodies as "weight changes."

Q: What is the official information about Algicler and driving or operating machinery?

The official label for Algicler lists central nervous system effects, such as dizziness, drowsiness, and somnolence (sleepiness), as potential side effects. Regulators typically advise caution regarding tasks requiring alertness, such as driving or operating machinery, when such effects are reported.

Q: Are there any known interactions between Algicler and common herbal supplements?

Patient counseling information from official sources emphasizes the importance of informing a healthcare professional regarding all prescription and over-the-counter medicines. This general guidance includes vitamins, supplements, and any herbal products currently being used.

Q: Does consuming alcohol affect the way Algicler works?

Official documents note that it is unknown if consuming alcohol affects the way Algicler works in the body. However, regulatory warnings indicate that both the medicine and alcohol may increase the risk of gastrointestinal bleeding.

Q: Does Algicler work better if taken in the morning or at night?

Official pharmacokinetic research has explored how the time of day affects the medicine's absorption. Studies indicate that the amount of the drug absorbed into the system (the extent of absorption) may be slightly lower when administered in the evening compared to the morning.

Q: Has Algicler been studied in children or adolescents?

Official prescribing information and regulatory approvals are typically focused on detailing the use and appropriate dosing for adult patients. For most forms of the medicine, specific regulatory approval and dosing information are often not established for children or adolescents.

Q: Is there a generic version of Algicler available?

The active ingredient in this medicine, Diclofenac, is officially described as a generic drug. Due to its status, multiple formulations are available on the market.

Q: Does Algicler affect mood or cause feelings of anxiety?

The official list of occasional adverse reactions includes effects on the nervous system. The reported symptoms listed by regulatory authorities in this category include anxiety and depression.

Q: Does Algicler have any 'black box' warnings listed in the official documentation?

Yes, the official U.S. regulatory label contains a prominent safety statement known as a Boxed Warning. This warning highlights the potential for serious cardiovascular thrombotic events (such as heart attack and stroke) and serious gastrointestinal adverse events (such as bleeding, ulceration, and perforation).

How should Algicler be stored and disposed of?

The official regulatory guidelines for storing and disposing of Algicler (Diclofenac) ensure its stability and safe removal.

Official Storage Requirements

Constraint Requirement
Temperature Store at room temperature, typically between 15 C and 30 C (59 F and 86 F), or not above 25 C depending on the formulation.
Environment Keep away from heat, moisture, and direct light. It must be kept from freezing.
Packaging Store in the tightly closed, original container to maintain potency and protect from environmental factors.

Disposal and Safety Rules

All forms of Algicler must be kept out of the sight and reach of children and pets at all times. Unused or expired medicine should be disposed of formally, preferably through a drug take-back program or specialized collection point, as directed by local regulations. If a take-back option is unavailable and the product is not on the FDA's flush list, mix the medicine with an undesirable substance (like coffee grounds or kitty litter), place it in a sealed bag or container, and discard it in the household trash. This prevents unintentional exposure and adheres to environmental safety instructions, which often discourage release into the aquatic environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Algicler  found in:

A-Z Index: